A systematic account of pathogenesis, diagnosis and pharmacotherapy of metabolic syndrome: Things we need to know

International Journal of Pharmacology

Volumn 6, Issue 4, 2010, Pages 430-437

  Mahajan, R ^a   Gupta, K ^b   Kapoor, V ^a  

^a Department of Pharmacology ^*  (India)

^b Adesh Institute of Medical Sciences and Research   (India)

Author keywords

Hyperlipidemia; Insulin resistance; Obesity; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOBESITY AGENT; BROMOCRIPTINE MESILATE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIMONABANT; RIVOGLITAZONE; TADALAFIL; TETRAHYDROLIPSTATIN; THIAZIDE DIURETIC AGENT; VILDAGLIPTIN;

ARTICLE; BARIATRIC SURGERY; BLOOD PRESSURE FLUCTUATION; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; CAUSAL ATTRIBUTION; CLINICAL FEATURE; CLINICAL TRIAL; DIET THERAPY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TREATMENT PLANNING;

EID: 77955615656     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2010.338.345     Document Type: Article

References (67)

1. Abbas F., B.W. Brown Jr, C. Lamendola, T. McLaughlin and G.M. Reaven, 2002. Relationship between obesity, insulin resistance and coronary heart disease risk. J. Am. Coll. Cardiol, 40: 937-943.
2. Alberti, K.G. and P.Z. Zimmet, 1998. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Med., 15: 539-553.
3. Boden, G., K. Sargrad, C. Homko, M. Mozzoli and T.P. Stein, 2005. Effect of a low-carbohydrate diet on appetite, Blood glucose levels and insulin resistance in obese patients with type 2 diabetes. Ann. Intern. Med., 142: 403-411.
4. Bogardus, C., S. Lillioja, D.M. Mott, C. Hollenbeck and G. Reaven, 1985. Relationship between degree of obesity and in vivo insulin action in man. Am. J. Physiol., 248: e286-e291.
5. Bokor, S., M.L. Frelut, A. Vania, C.G. Hadjiathanasiou and M. Anastasakou et al, 2008. Prevalence of metabolic syndrome in European obese children. Int. J. Pediatr. Obes., 3: 3-8.
6. Bolen, S., L. Feldman, J. Vassy, L. Wilson, H.C. Yeh and S. Marinopoulos et al., 2007. Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Int. Med., 147: 386-399.
7. Briton, E.A., 2008. Does the addition of fibrates to statin therapy have favorable risk to benefit ratio. Curr. Atheroscler. Rep., 10: 25-32.
8. CBC News, 2007. Anti-obesity drug no magic bullet. http://www.cbc.ca/health/story/2007/01/02/rimonabant.html.
9. Clough, G., M. Turzyniecka, L. Walter, A.J. Krentz and S.H. Wild et al., 2009. Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose Statin treatment. Diabetes., 58: 1185-1191.
10. Corona, G., G. Forti and M. Maggi, 2008. Why can patients with erectile dysfunction be considered lucky The association with testosterone deficiency andmetabolic syndrome. Aging Male., 11: 193-199.
11. Daskalopoulou, S.S., D.P. Mikharlrdrs and M. Elrsaf, 2004. Prevention and treatment of the metabolic syndrome. Angiology, 55: 589-612.
12. De Azevedo, G.D., E.C. Costa, M.T. Micussi and J.C. de Sa, 2008. Lifestyle modifications in polycystic ovary syndrome: role of physical exercise and importance of multidisciplinary approach (Article in Portuguese). Rev. Bras. Gynicol. Obstet., 30: 261-267.
13. Deedwania, P.C. and R. Gupta, 2006. Management issues in the metabolic syndrome. J. Assoc. Physicians. India, 54: 797-810.
14. Einhorn, D., G.M. Reaven, R.H. Cobin, E. Ford and O.P. Ganda et al., 2003. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract., 9: 237-252.
15. Elokdah, H., M. Abou-Gharbia, J.K. Hannan, G. McFarlane, C.P. Mugford, G. Krishnamurthy and D.L. Crandall, 2004. Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis and preclinical characterization. J. Med. Chem., 47: 3491-3494.
16. Elwood, P.C., J.E. Pickering and A.M. Fehily, 2007. Milk and dairy consumption, diabetes and the metabolic syndrome: the Caerphilly prospective study. J. Epidemiol. Community Health, 61: 695-698.
17. Encinosa, W.E., D.M. Bernard, C.C. Chen and C.A. Steiner, 2006. Healthcare utilization and outcomes after bariatric surgery. Med. Care, 44: 706-712.
18. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Assoc., 285: 2486-2497.
19. FDA, 2007. FDA, 2007. FDA briefing document NDA 21-888: Zimulti (rimonabant) tablets, 20 mg. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b-1-fda-backgrounder.pdf.
20. Feldeisen, S.E. and K.L. Tucker, 2007. Nutritional strategies in the prevention and treatment of metabolic syndrome. Applied Physiol. Nutr. Metab., 32: 46-60.
21. Ferrannini, E., S.M. Haffner, B.D. Mitchell and M.P. Stern, 1991. Hyperinsulinaemia: The key feature of a cardiovascular and metabolic syndrome. Diabetologia, 34: 416-422.
22. Fonseca, V., 2003. Effects of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med., 115: 42S-48S.
23. Ford, E.S., W.H. Grles and W.H. Dretz, 2002. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 287: 356-359.
24. Garcia-Compean, D., J.O. Jaquez-Quintana, J.A. Gonzalez-Gonzalez and H. Maldonado-Garza, 2009. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J. Gastroenterol., 15: 280-288.
25. Genuth, S., K.G. Alberti, P. Bennett, J. Buse and R. Defronzo et al, 2003. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 26: 3160-3167.
26. Grundy, S.M., H.B. Brewer, J.I. Cleeman, S.C. Smith, Jr. C. Lenfant and American Heart Association, National Heart Lung and Blood Institute, 2004. Definition of metabolic syndrome: Report of the National, Heart, Lung and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 109: 433-438.
27. Grundy, S.M., 2005. Metabolic syndrome: Therapeutic considerations. Handbook Exp. Pharmacol., 170: 107-133.
28. Haller, H., 1977. Epidemiology and associated risk factors of hyperlipoproteinemia (Article in German). Z. Gesamte. Inn. Med., 32: 124-128.
29. Han, S.H., M.J. Ouon and K.K. Koh, 2005. Beneficial vascular and metabolic effects of peroxisome proliferator activated receptor-alpha activators. Hypertension, 46: 1086-1092.
30. Hill, K.D., A.W. Eckhauser, A. Marney and N.J. Brown, 2009. Phosphodiesterase 5 inhibition improves beta cell function in the metabolic syndrome. Diabetes Care, 32: 857-859.
31. James, P.T., N. Rigby, R. Leach and International Obesity Task Force, 2004. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur. J. Cardiovasc. Prev. Rehabil., 11: 3-8.
32. Kahn, R., 2008. Metabolic syndrome-what is the clinical usefulness?. Lancet 371: 1892-1893.
33. Kapoor, V. and R. Mahajan, 2009. Chronotherapeutics. JK Sci.: J.Med. Edu. Res., 11: 109-110.
34. Katzmarzyk, P.T., A.S. Leon, J.H. Wilmore, J.S. Skinner, D.C. Rao, T. Rankinen and C. Bouchard, 2003. Targeting the metabolic syndrome with exercise: Evidence from the heritage family study. Med. Sci. Sports Exerc., 35: 1703-1709.
35. Kilo, C., N. Mezitis, R. Jain, J. Mersey, J. McGill and P. Raskin, 2003. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J. Diabetes Complications, 17: 307-313.
36. Kim, S.H. and G.M. Reaven, 2004. The metabolic syndrome: one step forward, two step back. Diab. Vase. Dis. Res., 1: 68-75.
37. Lakka, H.M., D.E. Laaksonen, T.A. Lakka, L.K. Niskanen, E. Kumpusalo, J. Tuomilehto and J.T. Salonen, 2002. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J. Am. Med. Assoc., 288: 2709-2716.
38. Lakka, T.A. and D.E. Laaksonen, 2007. Physical activity in prevention and treatment of the metabolic syndrome. Applied Physiol. Nutr. Metab., 32: 76-88.
39. Lewis, Jr. H.D., J.W. Davis, D.G. Archibald, W.E. Steinke and T.C. Smitherman et al, 1983. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans administration cooperative study. N. Engl. J. Med., 309: 396-403.
40. Liberopoulos, E.N., D.O. Mikbailidis and M.S. Elisaf, 2005. Diagnosis and management of the metabolic syndrome in obesity. Obes. Rev., 6: 283-296.
41. Liu, D., Z. Zhu and M. Tepel, 2008. The role of transient receptor potential channels in metabolic syndrome. Hypertens. Res., 31: 1989-1995.
42. Lovejoy, J.C., 2002. The influence of dietaiy fat on insulin resistance. Curr. Diab. Rep., 2: 435-440.
43. Mahajan, R. and K. Gupta, 2010. Drugs in pipeline for type-2 diabetes. Internet J. Pharmcol., Vol. 8(2). http://www.ispub.com/journal/the_internet_journal_of_pharmacology/volume_8_number_2_l9/article/drugs-in-pipeline-for-type-2-diabetes.html
44. Mahajan, R. and K. Gupta, 2010. Incretin mimetics and enhancers: New insulin secretagogues for type-2 diabetes. Biomed. Res., 21: 99-105.
45. Mahajan, R., 2009. Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes. Indian J. Pharmacol., 41: 197-198.
46. Mahajan, R., A.K. Gupta, K. Gupta, V. Kapoor, R.S. Gupta and G.K. Bedi, 2010. Efficacy and cost-effectiveness of insulin sensitizers in metabolic syndrome: A randomized control trial. Inventi Rapid: Clin. Pharm., Vol. 1(1).
47. Mannucci, E., M. Monami, C. Lamanna, G.F. Gensini and N. Marchionni, 2008. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes. Metab., 10: 1221-1238.
48. Meigs, J.B., 2002. Epidemiology of the metabolic syndrome, 2002. Am. J. Manage. Care., 8: S283-292.
49. Meigs, J.B., 2003. Epidemiology of insulin resistance syndrome. Curr Diab Rep., 3: 73-79.
50. Nakagawa, T., H. Hu, S. Zharikov, K.R. Tuttle and R.A. Short et al, 2006. A causal role for uric acid in fructose-induced metabolic syndrome. Am. J. Physiol. Renal Physiol., 290: F625-F631.
51. Reaven, G.M., 1988. Banting lecture 1988. Role of insulin resistance inhuman disease. Diabetes, 37: 1595-1607.
52. Rubins, H.B., 2000. Triglycerides and coronary heart disease: implications of recent clinical trials. J. Cardiovasc. Risk., 7: 339-345.
53. Rucker, D., R. Padwal, S.K. Li, C. Curiom and D.C. Lau, 2007. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ., 335: 1194-1199.
54. Sanchez-Torres, R.J. and H. Delgado-Osorio, 1997. The metabolic syndrome and its cardiovascular manifestations. Bol. Asoc. Med. P. R., 4: 271-280.
55. Schimke, K. and T.M. Davis, 2007. Drug evaluation: Rivoglitazone, a new oral therapy for the treatment of type 2 diabetes. Curr. Opin. Investig. Drugs., 8: 338-344.
56. Selvin, E., S. Bolen, H.C. Yeh, C. Wiley and L.M. Wilson et al, 2008. Cardiovascular outcomes in trials of oral diabetes medications: A systematic review. Arch. Int. Med., 168: 2070-2080.
57. Shick, S.M., R.R. Wing, M.L. Klem, M.T. McGuire, J.O. Hill and H. Seagle, 1998. Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet. J. Am. Diet. Assoc., 98: 408-413.
58. Sjostrim, L., 2008. Bariatric surgery and reduction in morbidity and mortality: Experiences from the SOS study. Int. J. Obes. (London), 31: S93-S97.
59. Snijder, M.B., A.A. van der Heijden, R.M. van Dam, C.D. Stehouwer and G.J. Hiddink et al, 2007. Is higher dairy consumption associated with lower body weight and fewer metabolic disturbances? The Hoorn Study. Am. J. Clin. Nutr., 85: 989-995.
60. Spellman, C.W., 2009. Achieving glycemic control: Cornerstone is the treatment of patients with multiple metabolic risk factors. J. Am. Osteopath. Assoc., 109: S8-S13.
61. Stumvoll, M., N. Nurjhan, G. Perriello, G. Dailey and J.E. Gerich, 1995. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med., 333: 550-554.
62. Tate, D.F., R.W. Jeffeiy, N.E. Sherwood and R.R. Wing, 2007. Long-term weight losses associated with prescription of higher physical activity goals. Are higher levels of physical activity protective against weight regain?. Am. J. Clin. Nutr., 85: 954-959.
63. Thielecke, F. and M. Boschmann, 2009. The potential role of green tea catechins in the prevention of the metabolic syndrome: A review. Phytochemistry, 70: 11-24.
64. Vitale, C., G. Marazzi, M. Volterrani, A. Aloisio, G. Rosano and M. Fini, 2006. Metabolic syndrome. Minerva Med., 97: 219-229.
65. WIN, 2007. Prescription medications for the treatment of obesity. Weight-control Information Network. http://win.niddk.nih.gov/publications/prescription.htm#fdameds.
66. Wilkes, J.J., D.J. Lloyd and N. Gekakis, 2009. Loss-of-function mutation in myostatin reduces TNF-alpha production and protects liver against obesity-induced insulin resistance. Diabetes, 58: 1133-1143.
67. Wing, R.R. and S. Phelan, 2005. Long-term weight loss maintenance. Am. J. Clin. Nutr., 82: 222S-225S.